Weight management articles from across Nature Portfolio

Glucagon-like peptide 1 (GLP1) analogues are licensed options for obesity, but new treatments are required to obtain better weight loss and to directly address other co-morbidities, such as non-alcoholic fatty liver disease. Research published in 2022 shows that co-agonist combinations of GLP1 with other hormones provide clinically important advances.

A large body of indisputable evidence shows that a certain treatment, commonly advocated by all healthcare professionals for a highly prevalent chronic medical condition, is associated with detrimental effects on health and an increased risk of mortality. This ‘treatment’, which needs eradicating from healthcare settings, is weight stigma.